About Us

Revolutionizing Cancer Care through Functional Precision Medicine:

An Introduction to KYAN Technologies

KYAN Technologies is leading the way in functional precision medicine, revolutionizing cancer care through the strategic use of advanced technology and expertise. Our devoted team aims to bridge the gap in cancer care by integrating small data AI and biological experiments to develop a truly personalized solution.

Our cutting-edge platform solution, Optim.AI™, empowers healthcare providers and scientists to make informed clinical and research decisions. This powerful tool provides critical insights, supporting healthcare providers and patients alike.
Our primary objective at KYAN is to enhance drug development and delivery, developing novel biopharmaceutical assets and expanding drug use. We are committed to providing better treatment options to as many patients as possible.

In addition to our groundbreaking technology, KYAN is committed to conducting extensive research studies across various cancer indications, including Colorectal and Breast Cancer. These studies not only contribute to the advancement of biopharma services but also aid in the development of novel biopharmaceutical assets.

  • Industry: Biotechnology Research
  • Company size: 2-10 employees
  • Founded: 2016

Meet Our Team

Our ex vivo analytic platform, Optim.AI™, empowers oncologists to better guide treatment for patients with truly personalized results

Scientific Co-founders

Edward Chow
Principal Investigator, Cancer ​Science Institute of Singapore, Assoc. Professor and Research ​Director, Pharmacology, ​School of Medicine, NUS
Dean Ho
Provost’s Chair Professor; ​Director, N.1 and WisDM; ​Head, Department of ​Biomedical Engineering,​ NUS
Chih-Ming Ho
UCLA Ben Rich-Lockheed ​Martin Professor Emeritus U.S. NAE Member Academia Sinica Academician C​o-founder of GeneFluidics


Wee Joo Chng, M.D.
Board Advisor, Based in Singapore Vice-President Biomedical Sciences Research, National University of Singapore Vice Dean, Yong Loo Lin School of Medicine, National University of Singapore Group Director Research Office, National University Health System
Steven Myint, M.D.
Board Advisor, Based in UK Professor of Microbiology & Immunology in Leicester and Dean of Medicine & Head of the Health Schools at the University of Surrey Adjunct Professor at Duke-NUS Medical School Chairman, Corporate Executive, Entrepreneur, Mentor and Advisor for Biotech and Life Sciences
Andreas Voss, M.D.
Board Advisor, Based in Switzerland M.D. from the University of Hamburg, Postdoctoral fellow at the UCSD. Board certified in internal medicine Previous roles: CEO International Caris Lifesciences, Global Clinical Development Oncology at Roche, Medical Director AstraZeneca Independent Director at APIS Assay Technologies
PPhal Singh, MBA, CA
Financial Advisor, Based in Singapore 25+ years CFO Degree in Finance & Accounting, MBA from University of Chicago and working experience as a regional/ global finance professional within companies in the Healthcare, Consumer Goods, Consulting, Industrial/ Manufacturing, Energy and Packaging industries Previous companies: Mundipharma, Amcor, Cameron, Tyco, Deloitte
Rasha Kandil
Regulatory Advisor, Based in UAE 25+ years in Regulatory Emerging Markets Certifications in advanced Regulatory Affairs and a BSc. degree in Pharmacy Previous companies: Mundipharma, NewBridge Pharma, Aspen Healthcare, Eli Lilly, Wyeth